cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.5939324
title: Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival"

description: Dataset related to article "Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival " Abstract <strong>Background: </strong>It is unclear whether invasive intraductal papillary mucinous neoplasm (IPMN) has different clinical and prognostic characteristics, beyond histological factors, when compared to pancreatic ductal adenocarcinoma (PDAC). <strong>Aims: </strong>compare prognostic features of resected PDAC and invasive IPMN METHODS: A retrospective study of patients resected for PDAC or invasive IPMN realized at Humanitas Cancer Center's Pancreatic Surgery Unit, Milan, Italy, between 2010 and 2016. Data recorded included patient demographics, onset symptoms, preoperative health status, tumor features, histology and surgical characteristics. Overall survival was estimated using Kaplan-Meier and prognostic factors for survival were assessed by multivariate Cox regression. <strong>Results: </strong>A total of 332 patients were included (PDAC, n = 289; invasive IPMN, n = 43). Patients with invasive IPMN had better overall survival than PDAC patients (median: 76.6 versus 25.6 months; 5-year OS rate: 65.4% vs. 14.2%; p &lt; 0.001). PDAC histology was associated with a significantly higher risk of death than IPMN (hazard ratio 1.815, 95% CI: 1.02, 3.24; p = 0.044). Survival was also worse with PDAC in early-stage disease (IA-IB-IIA, N0). In multivariate analysis, independent predictors of worse survival included perineural invasion, preoperative ASA physical status ≥3 and pain at diagnosis. <strong>Conclusions: </strong>Patients with IPMN had a better prognosis than PDAC patients, regardless of disease stage.
DOI: 10.5281/zenodo.5940945
title: Dataset related to article "Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy "

description: This record contains raw data related to article "Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy" <strong>Background: </strong> Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor β (PDGFR-β), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2-B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum-containing chemotherapy. <strong>Methods: </strong> A Fleming single-arm, single-stage, phase 2 trial to evaluate the activity of regorafenib (160 mg once a day by mouth for 3 weeks on/1 week off) was planned. The study was designed to reject the null hypothesis of an 8-week progression-free survival (PFS) rate ≤25% with a type I error of 0.10 and a statistical power of 80% at the alternative hypothesis of an 8-week PFS rate of ≥50% (≥8 of 19 evaluable patients progression-free at 2 months). <strong>Results: </strong> From June 2016 to November 2017, 19 patients were enrolled (11T/8TC). We observed partial response (PR) in 1 patient (1T) (5.3%), stable disease (SD) in 14 patients (9T/5TC) (73.7%), and progressive disease in 2 patients (1T/1TC) (10.5%), with a disease control rate of 78.9%. According to Choi-criteria, 13 patients (68.4%) achieved PR, and 2 patients SD (10.5%). The median PFS was 9.6 months whereas median overall survival was 33.8 months. The 8-week PFS rate was 78.9% (15 of 19 patients). Grade 3-4 treatment-related adverse events were observed in 10 patients (52.6%). <strong>Conclusions: </strong> The primary end point of this study was reached. The high rate of PR (Choi-criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies.
DOI: 10.5281/zenodo.5940944
title: Dataset related to article "Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy "

description: This record contains raw data related to article "Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy" <strong>Background: </strong> Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor β (PDGFR-β), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2-B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum-containing chemotherapy. <strong>Methods: </strong> A Fleming single-arm, single-stage, phase 2 trial to evaluate the activity of regorafenib (160 mg once a day by mouth for 3 weeks on/1 week off) was planned. The study was designed to reject the null hypothesis of an 8-week progression-free survival (PFS) rate ≤25% with a type I error of 0.10 and a statistical power of 80% at the alternative hypothesis of an 8-week PFS rate of ≥50% (≥8 of 19 evaluable patients progression-free at 2 months). <strong>Results: </strong> From June 2016 to November 2017, 19 patients were enrolled (11T/8TC). We observed partial response (PR) in 1 patient (1T) (5.3%), stable disease (SD) in 14 patients (9T/5TC) (73.7%), and progressive disease in 2 patients (1T/1TC) (10.5%), with a disease control rate of 78.9%. According to Choi-criteria, 13 patients (68.4%) achieved PR, and 2 patients SD (10.5%). The median PFS was 9.6 months whereas median overall survival was 33.8 months. The 8-week PFS rate was 78.9% (15 of 19 patients). Grade 3-4 treatment-related adverse events were observed in 10 patients (52.6%). <strong>Conclusions: </strong> The primary end point of this study was reached. The high rate of PR (Choi-criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies.
DOI: 10.6084/m9.figshare.19103567
title: Interview Protocol_Mentorship.docx

description: Interview protocol used in this study.
DOI: 10.6084/m9.figshare.19103567.v1
title: Interview Protocol_Mentorship.docx

description: Interview protocol used in this study.
DOI: 10.5281/zenodo.5941014
title: Dataset related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"

description: This record contains raw data related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors" Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor specimens, including surrogate biomarkers of the HCC immune class (based on intratumoral tertiary lymphoid structures, and glutamine synthase, CD3, and CD79 expression); and (ii) the relationship between HIRAE onset and subsequent treatment outcomes. Fifty-eight patients were included-20 (34%) received ICIs alone, and 38 (66%) received ICIs plus targeted agents as first- or further-line treatment. After a median time of 0.9 months (range, 0.4-2.7), nine patients (15.5%) developed grade ≥ 3 hepatitis, which was significantly associated with higher baseline ALT levels (<em>p</em> = 0.037), and an infectious HCC etiology (<em>p</em> = 0.023). ICIs were safely resumed in six out of nine patients. Time to treatment failure (TTF) was not significantly different in patients developing grade ≥ 3 hepatitis vs. lower grades (3.25 vs. 3.91 months, respectively; <em>p</em> = 0.81). Biomarker surrogates for the HCC immune class were not detected in patients developing grade ≥ 3 hepatitis. Grade ≥ 3 hepatitis has a benign course that does not preclude safe ICI reintroduction, without any detrimental effect on TTF.
DOI: 10.5281/zenodo.5941013
title: Dataset related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors"

description: This record contains raw data related to article "Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors" Risk factors for hepatic immune-related adverse events (HIRAEs) in patients with advanced/unresectable hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs) are unclear. We investigated: (i) clinical and morpho-pathological predictors of HIRAEs in 27 pretreatment tumor specimens, including surrogate biomarkers of the HCC immune class (based on intratumoral tertiary lymphoid structures, and glutamine synthase, CD3, and CD79 expression); and (ii) the relationship between HIRAE onset and subsequent treatment outcomes. Fifty-eight patients were included-20 (34%) received ICIs alone, and 38 (66%) received ICIs plus targeted agents as first- or further-line treatment. After a median time of 0.9 months (range, 0.4-2.7), nine patients (15.5%) developed grade ≥ 3 hepatitis, which was significantly associated with higher baseline ALT levels (<em>p</em> = 0.037), and an infectious HCC etiology (<em>p</em> = 0.023). ICIs were safely resumed in six out of nine patients. Time to treatment failure (TTF) was not significantly different in patients developing grade ≥ 3 hepatitis vs. lower grades (3.25 vs. 3.91 months, respectively; <em>p</em> = 0.81). Biomarker surrogates for the HCC immune class were not detected in patients developing grade ≥ 3 hepatitis. Grade ≥ 3 hepatitis has a benign course that does not preclude safe ICI reintroduction, without any detrimental effect on TTF.
DOI: 10.5523/bris.29p4r41hm0oz525k33jjvevrrd
title: Associated data for "A mixed methods analysis of participation in social contact surveys"

description: This is the quantitative and qualitative data used in the paper "A mixed methods analysis of participation in social contact surveys" and all associated code
DOI: 10.25934/pr00005714.1
title: Available IPD datapackage for study 'A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Alpha Therapies'

description: This study will assess the safety and efficacy of rituximab combined with MTX in participants with active rheumatoid arthritis (RA) who have had an inadequate response to anti-Tumor Necrosis (TNF) alpha therapy. The anticipated time in the study is up to 2 years and the target sample size is 500 participants. Eligible participants may receive re-treatment with rituximab under a separate protocol WA17531.
DOI: 10.5281/zenodo.5941099
title: Proxemics and Social Interactions in an Instrumented Virtual Reality Workshop

description: Supplemental code and dataset for the ACM CHI 2021 paper on "Proxemics and Social Interactions in an Instrumented Virtual Reality Workshop". In this research paper we instrumented Mozilla Hubs Cloud to record where participants where during the event. From there, we measured proxemic and plotted the activity along with some semi-structured interviews.
DOI: 10.3886/e161163
title: Trade, Productivity, and the Spatial Organization of Agriculture: Evidence from Brazil

description: This paper studies how regional productivity shocks in agriculture propagate to the rest of the economy via trade and migration linkages, shaping their aggregate effects on GDP, welfare, and agricultural employment. Using comprehensive agricultural data from Brazil, I estimate a general equilibrium model with a rich spatial structure to evaluate the effects of a critical shock in modern agriculture: the adaptation of soybeans to tropical regions. Results show that this shock increased Brazil's agricultural GDP by 4-6%, with the bulk of this impact coming from international trade. Because soybeans are land-intensive relative to other agricultural sectors, agricultural employment fell in tropical regions to which soybeans expanded. In other parts of the economy, however, agricultural employment rose substantially. Additionally, I show that general equilibrium effects have important implications for the analysis of the returns to agricultural research and the evaluation of the reduced-form effects of productivity shocks on agricultural employment.
DOI: 10.3886/e161163v1
title: Trade, Productivity, and the Spatial Organization of Agriculture: Evidence from Brazil

description: This paper studies how regional productivity shocks in agriculture propagate to the rest of the economy via trade and migration linkages, shaping their aggregate effects on GDP, welfare, and agricultural employment. Using comprehensive agricultural data from Brazil, I estimate a general equilibrium model with a rich spatial structure to evaluate the effects of a critical shock in modern agriculture: the adaptation of soybeans to tropical regions. Results show that this shock increased Brazil's agricultural GDP by 4-6%, with the bulk of this impact coming from international trade. Because soybeans are land-intensive relative to other agricultural sectors, agricultural employment fell in tropical regions to which soybeans expanded. In other parts of the economy, however, agricultural employment rose substantially. Additionally, I show that general equilibrium effects have important implications for the analysis of the returns to agricultural research and the evaluation of the reduced-form effects of productivity shocks on agricultural employment.
DOI: 10.25345/c5mz95
title: MassIVE MSV000088762 - Definition of germ cell lineage alternative splicing programs reveals a critical role for Quaking in specifying cardiac cell fate
title: Alternative splicing is critical for development. However, its role in the specification of the three embryonic germ layers is poorly understood. By performing RNA-Seq on human embryonic stem cells (hESCs) and derived endoderm, cardiac mesoderm, and ectoderm cell lineages, we detect distinct alternative splicing programs associated with each lineage. The most prominent splicing program differences are observed between definitive endoderm and cardiac mesoderm. Integrative multi-omics analyses link each program with lineage-specific RNA binding protein regulators, and further suggest a widespread role for Quaking (QKI) in the specification of cardiac mesoderm. Remarkably, knockout of QKI disrupts the cardiac mesoderm-associated alternative splicing program and formation of myocytes. These changes likely arise in part through reduced expression of BIN1 splice variants linked to cardiac development. Collectively, our results thus uncover alternative splicing programs associated with the three germ lineages and demonstrate an important role for QKI in the formation of cardiac mesoderm.
DOI: 10.6084/m9.figshare.19095266
title: Tinnitus Retraining therapy Trial

description: The purpose of the Tinnitus Retraining Therapy Trial (TRTT) is to assess the efficacy of Tinnitus Retraining Therapy (TRT) as a treatment for severe debilitating tinnitus in a randomized trial. TRT is a non-medical intervention that uses directive counseling (DC) and sound therapy (ST) to habituate the patient’s associated negative emotional reactions to tinnitus, its perception, and ultimately, its impact on the patient’s life. Johns Hopkins is the Data Coordination Center (DCC) for this the Tinnitus Retraining Therapy Trial, which will test the efficacy of TRT as a therapy for severely debilitating tinnitus. The DCC will not screen nor have any direct contact with trial participants. Study forms will be keyed by the Clinical Centers into a web-based data management system that uses SSL encryption during transmission of data from Clinical Centers to the DCC. The study forms’ data transmitted by the Clinical Centers and received by the DCC are identified by name code and study I.D. only. There are no personal identifiers on these forms.
DOI: 10.6084/m9.figshare.19095266.v1
title: Tinnitus Retraining therapy Trial

description: The purpose of the Tinnitus Retraining Therapy Trial (TRTT) is to assess the efficacy of Tinnitus Retraining Therapy (TRT) as a treatment for severe debilitating tinnitus in a randomized trial. TRT is a non-medical intervention that uses directive counseling (DC) and sound therapy (ST) to habituate the patient’s associated negative emotional reactions to tinnitus, its perception, and ultimately, its impact on the patient’s life. Johns Hopkins is the Data Coordination Center (DCC) for this the Tinnitus Retraining Therapy Trial, which will test the efficacy of TRT as a therapy for severely debilitating tinnitus. The DCC will not screen nor have any direct contact with trial participants. Study forms will be keyed by the Clinical Centers into a web-based data management system that uses SSL encryption during transmission of data from Clinical Centers to the DCC. The study forms’ data transmitted by the Clinical Centers and received by the DCC are identified by name code and study I.D. only. There are no personal identifiers on these forms.
DOI: 10.5063/f1t15239
title: Tow sex life table data of Menochilus sexmaculatus fungus treated

description: These are life table out puts that provided by Two sex Ms-chart life tables.
DOI: 10.5281/zenodo.5941123
title: Dataset related to article "Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung Cancer "

description: This record contains raw data related to article “Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung Cancer" <strong>Background: </strong> Non-small cell lung cancer (NSCLC) frequently presents when surgical intervention is no longer feasible. Despite local treatment with curative intent, patients might experience disease recurrence. In this context, accurate non-invasive biomarkers are urgently needed. We report the results of a pilot study on the diagnostic and prognostic role of circulating tumor cells (CTCs) in operable NSCLC. <strong>Methods: </strong> Blood samples collected from healthy volunteers (<em>n</em> = 10), nodule-negative high-risk individuals enrolled in a screening program (<em>n</em> = 7), and NSCLC patients (<em>n</em> = 74) before surgery were analyzed (4 mL) for the presence of cells with morphological features of malignancy enriched through the ISET<sup>®</sup> technology. <strong>Results: </strong> CTC detection was 60% in patients, while no target cells were found in lung cancer-free donors. We identified single CTCs (sCTC, 46%) and clusters of CTCs and leukocytes (heterotypic clusters, hetCLU, 31%). The prevalence of sCTC (sCTC/4 mL ≥ 2) or the presence of hetCLU predicted the risk of disease recurrence within the cohort of early-stage (I-II, <em>n</em> = 52) or advanced stage cases (III-IVA, <em>n</em> = 22), respectively, while other tumor-related factors did not inform prognosis. <strong>Conclusions: </strong> Cancer cell hematogenous dissemination occurs frequently in patients with NSCLC without clinical evidence of distant metastases, laying the foundation for the application of cell-based tests in screening programs. CTC subpopulations are fine prognostic classifiers whose clinical validity should be further investigated in larger studies.
DOI: 10.5281/zenodo.5941122
title: Dataset related to article "Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung Cancer "

description: This record contains raw data related to article “Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung Cancer" <strong>Background: </strong> Non-small cell lung cancer (NSCLC) frequently presents when surgical intervention is no longer feasible. Despite local treatment with curative intent, patients might experience disease recurrence. In this context, accurate non-invasive biomarkers are urgently needed. We report the results of a pilot study on the diagnostic and prognostic role of circulating tumor cells (CTCs) in operable NSCLC. <strong>Methods: </strong> Blood samples collected from healthy volunteers (<em>n</em> = 10), nodule-negative high-risk individuals enrolled in a screening program (<em>n</em> = 7), and NSCLC patients (<em>n</em> = 74) before surgery were analyzed (4 mL) for the presence of cells with morphological features of malignancy enriched through the ISET<sup>®</sup> technology. <strong>Results: </strong> CTC detection was 60% in patients, while no target cells were found in lung cancer-free donors. We identified single CTCs (sCTC, 46%) and clusters of CTCs and leukocytes (heterotypic clusters, hetCLU, 31%). The prevalence of sCTC (sCTC/4 mL ≥ 2) or the presence of hetCLU predicted the risk of disease recurrence within the cohort of early-stage (I-II, <em>n</em> = 52) or advanced stage cases (III-IVA, <em>n</em> = 22), respectively, while other tumor-related factors did not inform prognosis. <strong>Conclusions: </strong> Cancer cell hematogenous dissemination occurs frequently in patients with NSCLC without clinical evidence of distant metastases, laying the foundation for the application of cell-based tests in screening programs. CTC subpopulations are fine prognostic classifiers whose clinical validity should be further investigated in larger studies.
DOI: 10.25934/pr00005696.1
title: Available IPD datapackage for study 'A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis'

description: This study evaluated the efficacy and safety of rituximab in patients with active rheumatoid arthritis (RA).
DOI: 10.6084/m9.figshare.19103576
title: Data File for "The Effect of Medical Marijuana Laws on Extralegal Marijuana Prices"

description: Data file from: <br>Roland Malivert and Joshua Hall, “The Effect of Medical Marijuana Laws on Extralegal Marijuana Prices,” Atlantic Economic Journal 41(4) 2013: 455-456. <br>
DOI: 10.25934/pr00005690.1
title: Available IPD datapackage for study 'A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate'

description: This was a Phase II, randomized, open-label, multicenter study designed to evaluate the immune response to vaccines after administration of 1000 mg of rituximab in subjects with active rheumatoid arthritis (RA) who were receiving background methotrexate (MTX).
DOI: 10.5281/zenodo.5933948
title: To Which Out-Of-Distribution Object Orientations Are DNNs Capable of Generalizing?

description: Datasets created and used in the paper "To Which Out-Of-Distribution Object Orientations Are DNNs Capable of Generalizing?" https://arxiv.org/pdf/2109.13445.pdf
DOI: 10.5281/zenodo.5933947
title: To Which Out-Of-Distribution Object Orientations Are DNNs Capable of Generalizing?

description: Datasets created and used in the paper "To Which Out-Of-Distribution Object Orientations Are DNNs Capable of Generalizing?" https://arxiv.org/pdf/2109.13445.pdf
DOI: 10.48370/ofd/vbtwni/c1mkmp
title: Erysiphe friesii (Lév.) U. Braun & S. Takam. F-3255.tif

description: :unav
DOI: 10.48370/ofd/vbtwni
title: Erysiphe friesii (Lév.) U. Braun S. Takam., 3255

description: Fungarium Mikromycetes